180 Life Sciences EV/EBITDA
What is the EV/EBITDA of 180 Life Sciences?
The EV/EBITDA of 180 Life Sciences Corp. is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on NASDAQ compared to 180 Life Sciences
What does 180 Life Sciences do?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Companies with ev/ebitda similar to 180 Life Sciences
- Halo Collective has EV/EBITDA of N/A
- Genetron Ltd has EV/EBITDA of N/A
- Immunome has EV/EBITDA of N/A
- CuriosityStream has EV/EBITDA of N/A
- Cornerstone FS Plc has EV/EBITDA of N/A
- Yuxing InfoTech Investment has EV/EBITDA of N/A
- 180 Life Sciences has EV/EBITDA of N/A
- Anglo African Oil & Gas Plc has EV/EBITDA of N/A
- North Peak Resources has EV/EBITDA of N/A
- Casablanca has EV/EBITDA of N/A
- Predictive Oncology has EV/EBITDA of N/A
- Theranexus SA has EV/EBITDA of N/A
- 49 North Resources has EV/EBITDA of N/A